Claraphi Advisory Network, LLC Crispr Therapeutics Ag Transaction History

Claraphi Advisory Network, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $604,887 - $859,796	-5,489 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $321,377 - $515,943	-3,187 Reduced 36.73%	5,489 $889,000
Q1 2021 Apr 30, 2021	SELL	$110.72 - $210.04 $243,694 - $462,298	-2,201 Reduced 20.24%	8,676 $1.06 Million
Q4 2020 Feb 05, 2021	BUY	$79.67 - $173.23 $353,734 - $769,141	4,440 Added 68.98%	10,877 $1.67 Million
Q3 2020 Nov 13, 2020	BUY	$78.5 - $100.64 $186,908 - $239,623	2,381 Added 58.7%	6,437 $538,000
Q2 2020 Aug 14, 2020	BUY	$38.5 - $76.05 $156,156 - $308,458	4,056 New	4,056 $298,000

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.18B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Claraphi Advisory Network, LLC, based on Form 13F filings with the SEC.

Stay updated on Claraphi Advisory Network, LLC with notifications on news.